DMAC DIAMEDICA THERAPEUTICS INC revenue, earnings and financials
For the quarter ended June 30, 2026, DIAMEDICA THERAPEUTICS INC reported revenue of n/a, net income of −$10.1M and diluted EPS of n/a; for the fiscal year ended December 2025 revenue was n/a.
DMAC annual revenue and earnings
- Fiscal year ended Dec 2025: revenue n/a, gross profit n/a, operating income −$34.4M, net income −$32.8M (margin n/a), EPS n/a
- Fiscal year ended Dec 2024: revenue n/a, gross profit n/a, operating income −$26.7M, net income −$24.4M (margin n/a), EPS n/a
- Fiscal year ended Dec 2023: revenue n/a, gross profit n/a, operating income −$21.3M, net income −$19.4M (margin n/a), EPS n/a
- Fiscal year ended Dec 2022: revenue n/a, gross profit n/a, operating income −$14.0M, net income −$13.7M (margin n/a), EPS n/a
- Fiscal year ended Dec 2021: revenue n/a, gross profit n/a, operating income −$13.6M, net income −$13.6M (margin n/a), EPS −$0.65
DMAC quarterly revenue and earnings
- Quarter ended Jun 30, 2026: revenue n/a, net income −$10.1M, EPS n/a
- Quarter ended Mar 31, 2026: revenue n/a, net income −$10.0M, EPS n/a
- Quarter ended Dec 31, 2025 (from the annual report): revenue n/a, net income −$8.74M, EPS n/a
- Quarter ended Sep 30, 2025: revenue n/a, net income −$8.62M, EPS n/a
- Quarter ended Jun 30, 2025: revenue n/a, net income −$7.70M, EPS n/a
- Quarter ended Mar 31, 2025: revenue n/a, net income −$7.71M, EPS n/a
- Quarter ended Dec 31, 2024 (from the annual report): revenue n/a, net income −$7.90M, EPS n/a
- Quarter ended Sep 30, 2024: revenue n/a, net income −$6.27M, EPS n/a
- Quarter ended Jun 30, 2024: revenue n/a, net income −$5.12M, EPS n/a
- Quarter ended Mar 31, 2024: revenue n/a, net income −$5.15M, EPS n/a
- Quarter ended Dec 31, 2023 (from the annual report): revenue n/a, net income −$5.16M, EPS n/a
- Quarter ended Sep 30, 2023: revenue n/a, net income −$4.47M, EPS n/a
- Quarter ended Jun 30, 2023: revenue n/a, net income −$4.48M, EPS n/a
- Quarter ended Mar 31, 2023: revenue n/a, net income −$5.27M, EPS n/a
- Quarter ended Dec 31, 2022 (from the annual report): revenue n/a, net income −$3.75M, EPS n/a
- Quarter ended Sep 30, 2022: revenue n/a, net income −$3.06M, EPS n/a
- Quarter ended Jun 30, 2022: revenue n/a, net income −$3.36M, EPS n/a
- Quarter ended Mar 31, 2022: revenue n/a, net income −$3.51M, EPS n/a
- Quarter ended Dec 31, 2021 (from the annual report): revenue n/a, net income −$3.25M, EPS −$0.11
- Quarter ended Sep 30, 2021: revenue n/a, net income −$3.45M, EPS −$0.18
DMAC cash flow, buybacks and dividends
- Fiscal year ended Dec 2025: operating cash flow −$29.1M, share buybacks n/a
- Fiscal year ended Dec 2024: operating cash flow −$22.1M, share buybacks n/a
- Fiscal year ended Dec 2023: operating cash flow −$18.7M, share buybacks n/a
- Fiscal year ended Dec 2022: operating cash flow −$11.5M, share buybacks n/a
- Fiscal year ended Dec 2021: operating cash flow −$12.3M, share buybacks n/a
DMAC balance sheet
- Jun 30, 2026: cash $5.13M, total assets $45.0M, total liabilities n/a, shareholders' equity $38.3M
- Mar 31, 2026: cash $4.87M, total assets $53.1M, total liabilities n/a, shareholders' equity $47.2M
- Dec 31, 2025: cash $15.6M, total assets $61.4M, total liabilities n/a, shareholders' equity $56.1M
- Sep 30, 2025: cash $3.33M, total assets $57.0M, total liabilities n/a, shareholders' equity $51.6M
- Jun 30, 2025: cash $4.11M, total assets $31.5M, total liabilities n/a, shareholders' equity $27.2M
- Mar 31, 2025: cash $2.59M, total assets $38.8M, total liabilities n/a, shareholders' equity $34.0M
- Dec 31, 2024: cash $3.03M, total assets $46.3M, total liabilities n/a, shareholders' equity $40.7M
- Sep 30, 2024: cash $4.13M, total assets $52.5M, total liabilities n/a, shareholders' equity $48.0M
Is DMAC profitable?
No. DIAMEDICA THERAPEUTICS INC lost $37.5M over the last four quarters.